Printer Friendly

BIOCHEM REVENUES INCREASE 85 PERCENT

 BIOCHEM REVENUES INCREASE 85 PERCENT
 LAVAL, Quebec, April 1 /PRNewswire/ -- Revenues for BioChem Pharma


Inc. (NASDAQ: BCHXF; Toronto, Montreal: BCH) for the fiscal year ended Jan. 31. 1992, totalled $30.3 million, nearly double the previous year's revenues of $16.4 million.
 Net earnings were $12.7 million, or $0.37 per share, compared with a net loss of $925,203 or $0.03 per share, last year. The 1992 earnings include a $17.1 million profit on dilution following the issue of capital stock of its affiliated company, North American Vaccine, Inc. ("NAVA") (AMEX: NVX).
 Prior to its profit on dilution, income tax, minority interest and its share of the NAVA loss, BioChem had a loss of $225,463 for its 1992 fiscal year, compared with a profit of $433,990 for the previous year.
 Research and development expenditures for the year were $9.6 million, compared with $6.3 million the preceding year. As of Jan. 31, 1992, total assets were $109,117,054, compared with $51,938,782 a year before, and shareholders' equity was $83,956,914, compared with $39,750,640. The company's cash position at the end of the year was $37.4 million, compared with $26.9 million the previous year.
 BioChem Pharma Inc. is a pharmaceutical company dedicated to the research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases.
 -0- 4/1/92
 /CONTACT: Thomas Babinski of BioChem Pharma, 514-681-1744, or (home) 514-344-9958, or Gerard Berube or Luc Beauregard of National Public Relations, 514-843-7171, for BioChem Pharma/
 (BCHXF) CO: BioChem Pharma Inc. ST: Quebec IN: MTC SU: ERN


TQ-TS -- NY029 -- 3835 04/01/92 10:43 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1992
Words:282
Previous Article:COLTEC HOLDINGS ANNOUNCES FURTHER EXTENSION OF ITS TENDER OFFER
Next Article:OHM CORPORATION AWARDED $57.9 MILLION SUPERFUND PROJECT
Topics:


Related Articles
BIOCHEM RECORDS EXCELLENT THIRD QUARTER
94 PERCENT OF ENZO BIOCHEM DEBENTURES CONVERTED TO STOCK; ENZO GAINS $32.5 MILLION IN NET WORTH FROM $28.2 MILLION CONVERSION
BIOCHEM PHARMA DOUBLES ITS REVENUES IN FIRST QUARTER
BIOCHEM GETS ANOTHER MAJOR SALES CONTRACT IN EUROPE
BIOCHEM PHARMA QUARTERLY RESULTS - CONTINUED GROWTH IN RESEARCH AND DEVELOPMENT AND REVENUES
1992-1993 FISCAL YEAR: BIOCHEM PHARMA MAINTAINS SOLID FINANCIAL POSITION
BIOCHEM PHARMA ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
BIOCHEM PHARMA PURCHASES AN EQUITY STAKE IN ANTISOMA
Vertex and BioChem Advance Phase II Clinical Development of Cancer Multidrug Resistance Inhibitor, VX-710, in U.S. and Canada
BIOCHEM PHARMA CONCLUDES SPIN-OFF OF NEWLY-FORMED CLINICHEM DEVELOPMENT INC.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters